

Francesco Torino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/396488/publications.pdf>

Version: 2024-02-01

40
papers

1,893
citations

516710

16
h-index

289244

40
g-index

41
all docs

41
docs citations

41
times ranked

3292
citing authors

#	ARTICLE	IF	CITATIONS
1	Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic. <i>Cancers</i> , 2022, 14, 593.	3.7	6
2	Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1152.	4.1	13
3	Immune Checkpoint Inhibitors as a Threat to the Hypothalamusâ€Pituitary Axis: A Completed Puzzle. <i>Cancers</i> , 2022, 14, 1057.	3.7	4
4	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. <i>Frontiers in Oncology</i> , 2022, 12, 798517.	2.8	9
5	Self-care behaviours in older adults treated with oral anticancer agents: A qualitative descriptive study. <i>European Journal of Oncology Nursing</i> , 2022, 58, 102139.	2.1	2
6	Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3995.	4.1	8
7	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. <i>Frontiers in Endocrinology</i> , 2022, 13, 840971.	3.5	2
8	Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. <i>Cancers</i> , 2022, 14, 2594.	3.7	3
9	Self-care behaviors in patients with cancer treated with oral anticancer agents: a systematic review. <i>Supportive Care in Cancer</i> , 2022, 30, 8465-8483.	2.2	3
10	MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 1059.	2.5	1
11	Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. <i>Cancers</i> , 2021, 13, 4213.	3.7	15
12	A scoping review on the â€œburned outâ€ or â€œburnt outâ€ testicular cancer: When a rare phenomenon deserves more attention. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103452.	4.4	5
13	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10672.	4.1	5
14	Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 582394.	2.8	17
15	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. <i>Cancers</i> , 2020, 12, 2237.	3.7	71
16	Immune-checkpoint inhibitors from cancer to COVIDâ€™19: A promising avenue for the treatment of patients with COVIDâ€™19 (Review). <i>International Journal of Oncology</i> , 2020, 58, 145-157.	3.3	55
17	Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms. <i>Frontiers in Endocrinology</i> , 2019, 10, 757.	3.5	6
18	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019, 11, 38.	3.7	378

#	ARTICLE	IF	CITATIONS
19	Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. <i>Pharmacological Research</i> , 2018, 131, 1-6.	7.1	5
20	Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art. <i>European Endocrinology</i> , 2018, 14, 62.	1.5	58
21	Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 37.	3.5	4
22	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	1.8	15
23	Clinical utility of lanreotide Autogel^{®®} in gastroenteropancreatic neuroendocrine tumors. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3459-3470.	4.3	9
24	Endocrinological side-effects of immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 278-287.	2.4	115
25	Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 101-110.	4.4	10
26	Effects of mutations in Wnt/ β 2-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity – Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2942-2976.	4.1	137
27	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. <i>Oncotarget</i> , 2016, 7, 72758-72766.	1.8	73
28	AMBRA1 and SQSTM1 expression pattern in prostate cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 1577-1586.	4.9	23
29	Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. <i>Oncologist</i> , 2015, 20, 1111-1118.	3.7	15
30	Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 27-42.	4.4	68
31	Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 489-490.	2.3	16
32	Circulating tumor cells in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2013, 39, 759-772.	7.7	49
33	Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs. <i>Thyroid</i> , 2013, 23, 1345-1366.	4.5	93
34	The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 283-305.	4.4	8
35	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164.	3.7	102
36	Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, R21-R33.	3.1	35

#	ARTICLE	IF	CITATIONS
37	Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. <i>Anticancer Research</i> , 2010, 30, 4721-30.	1.1	5
38	Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 219-228.	27.6	182
39	Combined effects of 5-Fluorouracil, Folinic acid and Oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 5.	8.6	18
40	Triazene compounds: Mechanism of action and related DNA repair systems. <i>Pharmacological Research</i> , 2007, 56, 275-287.	7.1	247